From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2– breast cancer
Abstract
Despite the initial clinical success of CDK4/6 inhibitors in combination with endocrine therapy, the development of resistance (intrinsic and acquired) remains a significant challenge in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC). Recent advances have shed light on resistance mechanisms that primarily affect the cell cycle machinery, including loss of Rb function, cyclin E1 overexpression leading to CDK2 activation, and CDK6 or CDK4 upregulation. These alterations disrupt the G1/S checkpoint and drive proliferation independently of CDK4/6 inhibition. In contrast, non–cell cycle-related pathways, such as PI3K/AKT/mTOR and FGFR signaling, may also contribute but appear less central in many resistant tumors. These findings have highlighted the need for next-generation therapeutic approaches aimed at overcoming resistance. Selective inhibition of CDK2 and/or CDK4 is among the most promising strategies, potentially offering a more favorable therapeutic index while maintaining anti-proliferative efficacy. Early-phase trials of selective CDK2/CDK4 inhibitors, alone or combined, have shown encouraging activity, particularly in tumors resistant to prior CDK4/6 inhibition. However, most available data are limited to small, selected cohorts, underscoring the need for larger, randomized studies. Another emerging approach targets lysine acetyltransferases (KAT), key epigenetic regulators of…
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.